Literature DB >> 19020499

CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues.

Victoria B Risbrough1, Mark A Geyer, Richard L Hauger, Sarah Coste, Mary Stenzel-Poore, Wolfgang Wurst, Florian Holsboer.   

Abstract

Corticotropin-releasing factor (CRF) peptides and their receptors have crucial roles in behavioral and endocrine responses to stress. Dysregulation of CRF signaling has been linked to post-traumatic stress disorder, which is associated with increased startle reactivity in response to threat. Thus, understanding the mechanisms underlying CRF regulation of startle may identify pathways involved in this disorder. Here, we tested the hypothesis that both CRF1 and CRF2 receptors contribute to fear-induced increases in startle. Startle responses of wild type (WT) and mice with null mutations (knockout, KO) for CRF1 or CRF2 receptor genes were measured immediately after footshock (shock sensitization) or in the presence of cues previously associated with footshock (ie fear-potentiated startle, FPS). WT mice exhibited robust increases in startle immediately after footshock, which was dependent upon contextual cues. This effect was completely absent in CRF1 KO mice, and significantly attenuated in CRF2 KO mice. In contrast, CRF1 and CRF2 KO mice exhibited normal potentiation of startle by discrete conditioned cues. Blockade of both receptors via CRF1 receptor antagonist treatment in CRF2 KO mice also had no effect on FPS. These results support an additive model of CRF1 and CRF2 receptor activation effects on potentiated startle. These data also indicate that both CRF receptor subtypes contribute to contextual fear but are not required for discrete cued fear effects on startle reactivity. Thus, we suggest that either CRF1 or CRF2 could contribute to the increased startle observed in anxiety disorders with CRF system abnormalities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020499      PMCID: PMC2900918          DOI: 10.1038/npp.2008.205

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  65 in total

1.  Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist.

Authors:  Glenn R Valdez; Eric P Zorrilla; Jean Rivier; Wylie W Vale; George F Koob
Journal:  Brain Res       Date:  2003-08-08       Impact factor: 3.252

2.  Evidence of contextual fear after lesions of the hippocampus: a disruption of freezing but not fear-potentiated startle.

Authors:  K A McNish; J C Gewirtz; M Davis
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

3.  Light-enhanced startle: further pharmacological and behavioral characterization.

Authors:  David L Walker; Michael Davis
Journal:  Psychopharmacology (Berl)       Date:  2001-10-17       Impact factor: 4.530

4.  Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala.

Authors:  Vaishali P Bakshi; Stephanie Smith-Roe; Sarah M Newman; Dimitri E Grigoriadis; Ned H Kalin
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

5.  Acoustic startle, prepulse inhibition, and fear-potentiated startle measured in rhesus monkeys.

Authors:  James T Winslow; Lisa A Parr; Michael Davis
Journal:  Biol Psychiatry       Date:  2002-06-01       Impact factor: 13.382

6.  Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress.

Authors:  Sayamwong E Hammack; Megan J Schmid; Matthew L LoPresti; Andre Der-Avakian; Mary Ann Pellymounter; Alan C Foster; Linda R Watkins; Steven F Maier
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

7.  The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol.

Authors:  A D Lê; S Harding; W Juzytsch; P J Fletcher; Y Shaham
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

8.  Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation.

Authors:  Benno Roozendaal; Kristen L Brunson; Brian L Holloway; James L McGaugh; Tallie Z Baram
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-02       Impact factor: 11.205

9.  GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice.

Authors:  Victoria B Risbrough; Jesse D Brodkin; Mark A Geyer
Journal:  Neuropsychopharmacology       Date:  2002-10-03       Impact factor: 7.853

10.  Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress.

Authors:  Mary Ann Pelleymounter; Margaret Joppa; Nicholas Ling; Alan C Foster
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

View more
  26 in total

1.  Reduction of fear-potentiated startle by benzodiazepines in C57BL/6J mice.

Authors:  Kiersten S Smith; Edward G Meloni; Karyn M Myers; Ashlee Van't Veer; William A Carlezon; Uwe Rudolph
Journal:  Psychopharmacology (Berl)       Date:  2010-10-05       Impact factor: 4.530

Review 2.  Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Frank M Dautzenberg; James B Lohr; Sandra Braun; Robert H Oakley
Journal:  Neuropharmacology       Date:  2011-11-25       Impact factor: 5.250

3.  Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry.

Authors:  Jan M Schilling; Weihua Cui; Joseph C Godoy; Victoria B Risbrough; Ingrid R Niesman; David M Roth; Piyush M Patel; John C Drummond; Hemal H Patel; Alice E Zemljic-Harpf; Brian P Head
Journal:  Behav Brain Res       Date:  2014-03-19       Impact factor: 3.332

4.  Susceptibility to PTSD-like behavior is mediated by corticotropin-releasing factor receptor type 2 levels in the bed nucleus of the stria terminalis.

Authors:  Maya Lebow; Adi Neufeld-Cohen; Yael Kuperman; Michael Tsoory; Shosh Gil; Alon Chen
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

5.  Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Sandra Braun; Judith Hernandez-Aranda; Christine C Hudson; Eric Gutknecht; Frank M Dautzenberg; Robert H Oakley
Journal:  Regul Pept       Date:  2013-06-29

6.  Corticotropin-releasing factor and noradrenergic signalling exert reciprocal control over startle reactivity.

Authors:  Jodi E Gresack; Victoria B Risbrough
Journal:  Int J Neuropsychopharmacol       Date:  2010-12-21       Impact factor: 5.176

Review 7.  Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.

Authors:  Richard L Hauger; Victoria Risbrough; Robert H Oakley; J Alberto Olivares-Reyes; Frank M Dautzenberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 8.  The genetics of anxiety-related negative valence system traits.

Authors:  Jeanne E Savage; Chelsea Sawyers; Roxann Roberson-Nay; John M Hettema
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-05-19       Impact factor: 3.568

9.  The central nucleus of the amygdala and corticotropin-releasing factor: insights into contextual fear memory.

Authors:  Matthew W Pitts; Cedomir Todorovic; Thomas Blank; Lorey K Takahashi
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

Review 10.  Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety.

Authors:  Michael Davis; David L Walker; Leigh Miles; Christian Grillon
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.